CompletedPhase 1NCT04647903

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

Studying Narcolepsy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vallon Pharmaceuticals, Inc.
Principal Investigator
Timothy Whitaker, M
Vallon Pharmaceuticals, Inc.
Intervention
ADAIR 10 mg IR tablets(drug)
Enrollment
55 target
Eligibility
18-55 years · All sexes
Timeline
2020 – 2021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04647903 on ClinicalTrials.gov

Other trials for Narcolepsy

Additional recruiting or active studies for the same condition.

See all trials for Narcolepsy →

← Back to all trials